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Abstract:  
Increasing evidence shows that discrepancies exist among in vitro cytotoxicity methods resulting in 
unreliable drug toxicity profiles. This is particularly criticial for cell lines such as gliomas which are 
histologically and genetically heterogeneous. The high level of variation in these cells makes comparative 
analysis difficult and is a severe limitation for the usefulness of high-throughput screening methods. Here 
we examine variations between four conventional in vitro cytotoxicity assays (MTT, Alamar Blue, Acid 
Phosphatase and Trypan Blue) for assessing the viable cell number following treatment of two human 
glioblastoma cell lines (U87MG and U373MG) with different chemical agents (carboplatin, etoposide, 
paraquat). The variations in IC50 values between the four assays suggest that even when combining several 
endpoints such as mitochondrial functions, lysosomal activity, and membrane integrity, a reliable and 
uniform toxicity profile was not achieved. Because of these variations between cytotoxicity assays using 
compounds with varying mechanisms of cytotoxicity, then it is possible that the true IC50 value of valuable 
and beneficial compounds for glioblastoma may have been missed through over/underestimation. This 
highlights the importance of reliability and accuracy in pre-animal models such as in vitro models of 
cytotoxicity for better predictive in vivo responses. 
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1. Introduction  
 The term cytotoxicity is commonly used to refer to the potential of a compound to induce variations in 
the cellular behaviour and essential processes that subsequently trigger cell death or cause a large decrease 
in cell survival (Niles and Riss, 2015). Bearing in mind that cells are able to exhibit specific responses as a 
result of exposure to diverse chemicals or physical stresses, a considerable number of in vitro cytotoxicity 
assays are available.  These are generally classified on the basis of the endpoints they measure which usually 
involve a commom mechanism shared by most cell types. However, some assays may measure specific 
responses according to a particular cell type, e.g. motility for sperm cells and hemolysis for red blood cells. 
Currently, the common endpoints used for assessing cytotoxicity include membrane permeability, cellular 
metabolite content, mitochondrial functions, lysosomal functions and cell death (Mahto et al., 2010). Some 
features of the most popular in vitro methods for evaluating cytotoxicity are shown in Table 1.    
One of the stalwarts of in vitro chemosensitivity testing has for many years been the colorimetric MTT 
(3-(4,5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide) assay based on the reduction by 
intracellular dehydrogenases of the yellow tetrazolium salt to purple formazan crystals by viable cells. 
Originally developed by Mosmann (Mosmann, 1983), the MTT assay had several advantages over the pre-
existing technologies of cell counting and radio-labelling of nucleotides. The MTT assay proved to be a 
quick and convenient technique with lower technical requirements than some of the other methods and was 
rapidly adopted by investigators (Denizot and Lang, 1986). These advantages also led to the MTT assay 
being adapted for HTS (high throughput screening) as the process can be fully automated. Other 
colorimetric and fluorometric assays, such as the Alamar Blue (resazurin reduction), acid phosphatase (p-
nitrophenol phosphate hydrolysis), XTT (tetrazolium salt reduction) and SRB (sulforhodamine B amino 
acid complexation) have also been implemented for HTS, each with its own benefits and limitations (Niles 
et al., 2009,Rajalingham, 2016,Slater, 2001).  
The ability to measure the number of viable cells through in vitro HTS assays represents an important 
tool with applications in toxicological safety testing, oncological research, industrial microbiology studies, 
bioprocess monitoring and drug discovery (Szymanski et al., 2012,Macarron et al., 2011). Recently, 
increasing evidence has shown some discrepancies between the different methods which has led to either 
an underestimate or an overestimate of cytotoxicity leading to unreliable toxicity profiles (Rajalingham, 
2016). Therefore, it has become critical to establish the reliability of these widely used non-animal methods 
for assessing the potential cytotoxicity of chemicals and new therapeutic agents. This is particularly 
important if one takes into consideration the 3Rs ethic, Replace, Reduce, and Refine, where a concerted 
effort is focused on encouraging researchers to lower the level of reliance upon animal models for screening 
potential therapeutic compounds in both the discovery and development process (Baumans, 2004). 
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Exemplary of this concept is the total ban on animal testing in cosmetics which came into force with the 
Cosmetic Regulation no. 1223/2009 on March 13th, 2016. 
Further complications in the implementation of standardized, commercially available cytotoxicity 
testing methods, are the variations in response to drugs that may differ not only according to the drug but 
also according to the cell line being investigated. For example, an important consideration in the context of 
researching therapies for brain gliomas, is that all gliomas are histologically and genetically heterogeneous 
(DeAngelis, 2001,Inda et al., 2014), therefore they are also heterogeneous in their therapeutic responses. 
This high level of variation makes comparative analysis difficult and is a severe limitation for the usefulness 
of HTS methods. Gliomas derive from neoplastically transformed glial cells that constitute the supportive 
tissue of the brain, and their growth and proliferation impact brain structure and function (Sizoo et al., 
2010). The morbidity and mortality rates of gliomas have remained consistently high due to the 
heterogeneity of this disease, prognosis is typically poor and no substantial improvements in overall 
survival have been made over the past four decades (Anderson et al., 2008,Van Meir et al., 2010,Omuro 
and DeAngelis, 2013). The need for additional therapies is therefore ongoing and the development of more 
robust modelling systems will aid this progress, enabling the pharmaceutical industry to better target their 
resources against gliomas.                                                                                                                                                            
Previous work in our laboratory on cancer cells has indicated that for all of the previously mentioned 
assays, results vary between different drugs but yet, they always remain consistently elevated compared to 
the gold standard Trypan Blue (TB) exclusion method. At present, the simplicity and its low cost  maintain 
the TB exclusion assay as the gold standard method for determining cell numbers and for evaluating 
cytotoxicity. Although extensively used, through years important limitations have been attributed to this 
method: it is considered a time-consuming assay and when used for a large number of samples it can provide 
low precision results (Avelar-Freitas et al., 2014).  Furthermore, it is a subjective assay which can however 
easily be circumvented by blinding the samples to be counted. Additionally, Tramontina and colleagues 
have shown that exposing live cells to TB for longer than 5 min can cause inappropriate uptake of the dye 
into viable cells and therefore result in overestimation of dead cells in a sample (Tramontina et al., 2000).  
With this background, the aim of this study was to examine variations between four conventional in 
vitro cytotoxicity assays (MTT, Alamar Blue, Acid Phosphatase and Trypan Blue) for assessing the viable 
cell number following in vitro treatment of two human glioblastoma cell lines with different chemical 
agents. U87MG and U373MG are well established glioblastoma cell lines harbouring a range of different 
genetic lesions, and that represent a robust and reliable testing model for the comparison of cytotoxicity 
assays, allowing for both variations in drugs under investigation as well as the susceptibility or resistance 
of the cell line (Schmidt et al., 2013).  
4 
 
The four in vitro assays were compared using three agents that differ in their mode of action in triggering 
cytotoxic effects. Two anticancer agents were used, Carboplatin and Etoposide, which are mainly apoptotic 
in nature via DNA cross-linking/alkylation and topoisomerase II inhibition, respectively (Avgeropoulos 
and Batchelor, 1999). As a contrast the herbicide, paraquat, was also investigated since it is a well-known 
toxin that causes necrotic cell death via oxidative stress (Grabie et al., 1993,Pezzoli and Cereda, 2013). By 
comparing these frequently used enzymatic assays with the gold standard cell counting technique (TB 
assay), the study aims to provide medical researchers with an assessment of the reliability of these assays 
and possible pitfalls in some of the most relied upon methods in current usage.  
 
2. Materials and Methods   
2.1. Chemicals and reagents 
All chemicals, reagents and culture medium were supplied by Sigma Aldrich (St Louis, MO, USA) 
except where explicitly stated. Etoposide (TOCRIS, Bioscience, Bristol, UK), carboplatin and paraquat 
dichloride hydrate were dissolved in their appropriate vehicles and diluted to the required concentrations in 
cell culture medium.  
2.2. Culture of glioblastoma cell lines 
Human glioblastoma multiforme cell lines U373MG and U87MG (obtained from ECACC) were 
maintained in Eagle’s minimum essential medium (EMEM) supplemented with 10% FBS, 1% penicillin-
streptomycin and 1% L-glutamine, in a humidified incubator at 37°C and 5% CO2. Fresh medium was 
changed every 3 days and cells were sub-cultured at ~80% confluency.  
2.3. Experimental protocol  
All experiments were conducted on cells seeded at a density of 2.4 x 106/cm2 incubated for 24 h post-
seeding in 6 cm cell culture dishes and 48 h post-seeding in 96-well microtitre plates. Following the 
appropriate incubation time, medium was discarded and replaced with fresh medium containing varying 
concentrations of the compound of interest and incubated for a further 48 h. 
2.4. MTT assay  
This assay, as previously mentioned, relies on the reduction by intracellular NAD(P)H-dependent 
dehydrogenases of viable cells, of the soluble and pale yellow tetrazolium salt, MTT, into insoluble and 
purple formazan crystals, thus reflecting the number of metabolically active cells present in a sample 
(Berridge et al., 2005). 
After 48 h drug exposure, the MTT colorimetric assay was performed on the 96-well plates. Ten µL of 
MTT solution in PBS (5 µg/mL) were added to each well, including medium only used as negative control,  
and returned to the incubator for 3 h. Medium was then removed from each well, replaced with 100 µL 
DMSO for solubilisation of the formazan crystals and the plate was placed on a shaker for 20 min. 
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Absorbance was read at 570 nm with reference wavelength of 690 nm on a Sunrise TecanTM microplate 
reader (Tecan Trading AG, Switzerland). Viable cell count was assessed as a percentage relative to 
untreated cells.  
2.5. Trypan blue exclusion assay  
Trypan Blue is a negatively charged, relatively small molecule (960 Da) that is cell membrane 
impermeable. However, in cells with compromised cell membranes, it is able to penetrate and bind to 
different intracellular proteins, giving cells a bluish colour readily observable under a microscope. Thus, 
this assay is able to discriminate in a given population between viable cells and cells with damaged 
membranes that are usually considered to be dead/dying (Strober, 2015). 
After 48 h drug exposure, cells were harvested from 6 cm cell culture dishes by trypsinization, the pellet 
was resuspended in 1 mL of medium and 100 µL of this suspension was diluted with the appropriate volume 
of trypan blue for cell counting on an improved Neubauer Haemocytometer (Weber Scientific Internation 
Ltd, UK). Viable and non-viable cells were counted under light microscopy and are reported as a percentage 
of the total cell number for each drug treatment.  
2.6. Acid phosphatase assay  
The acid phosphatase assay developed by Connolly et al. (Connolly et al., 1986) measures the activity 
of lysosomal acid phosphatases. In viable cells, the synthetic substrate p-nitrophenyl phosphate is 
hydrolysed to p-nitrophenol by intracellular acid phosphatases, producing a colour change in an alkaline 
environment that can be measured at 405 nm. This enables a correlation to be drawn between absorbance 
and viable cell number (Ivanov et al., 2014). 
After 48 h drug exposure, medium was removed from all wells and cells were washed twice with PBS. 
To each well, including medium only used as negative control, 100 L of acid phosphatase buffer (0.1 M 
sodium acetate, 0.1% Triton X-100, pH 5) and 5 mM p-nitrophenyl phosphate were added to each well and 
returned to the 37°C incubator for 1 h. The reaction was stopped by adding 50 µL 0.3 M NaOH to each 
well and the plate read at 405 nm with a reference wavelength of 630 nm on a BioTek SynergyTM HT plate 
reader (Winooski, VT, USA). Viable cell count was assessed as a percentage relative to untreated cells.  
2.7. Alamar blue assay  
This assay is based on the reduction by mitochondrial enzymes of viable cells, of the active ingredient 
of Alamar Blue, resazurin, a blue water-soluble, non-toxic dye, into the fluorescent pink compound, 
resorufin, which can be quantified using a microplate fluorometer. Colour intensity is hence proportional 
to the amount of viable cells present in a sample (O'Brien et al., 2000). 
After 48 h drug exposure, 10 µL Alamar Blue reagent (1 mg/mL resazurin sodium salt in PBS) was 
added to each well, including medium only used as negative control, and incubated for a further 4 h to 
promote the reaction and the subsequent pink colour generation by metabolically active cells. The 
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absorbance was then read on a BioTek SynergyTM HT plate reader (Winooski, VT, USA) at 530 nm with a 
reference wavelength of 590 nm. Viable cell count was assessed as a percentage relative to untreated cells.  
2.8. Statistical methods 
All experiments were repeated independently a minimum of three times, unless stated otherwise and 
data are expressed as mean ± standard error of the mean (SEM). IC50 values were analysed using GraphPad 
Prism 7 using non-linear sigmoidal curve fitting with the normalized response or  the Excel add-in ed50v10. 
Statistical differences were determined using the Student’s t-test with p < 0.05 considered as statistically 
significant. 
 
3. Results and Discussion 
3.1 Changes in viable cell number associated with different in vitro assays following exposure to chemical 
compounds 
In the past two decades, the use of in vitro methods has become the most used alternative to animal 
experiments for evaluating hazardous effects induced by chemicals and for predicting in vivo human 
toxicity (Doke and Dhawale, 2015). Specifically, cell-based in vitro assays are considered major tools 
largely used for preliminary screening and ranking of new chemical entities through the drug discovery and 
development process (Eisenbrand et al., 2002). In the present study, variations between four conventional 
in vitro cytotoxicity assays in terms of the number of viable cells on two human glioblastoma cell lines in 
the presence of carboplatin, etoposide and paraquat were investigated (Fig. 1). The results show that in the 
majority of cases there are clear inter-assay differences for both cell lines since the toxicity profiles differ 
for the three individual compounds. A clear dose-response effect was observed for all assays and for all 
three compounds in the U87MG cell line (Fig. 1A-C). However, in U373MG cells an appreciable dose 
response-effect was observed for all assays only in the case of paraquat (Fig. 1F) and carboplatin with the 
exception of the Alamar Blue assay (Fig. 1D). No dose-response effect was observed in the presence of 
etoposide using the Alamar Blue and MTT assays (Fig. 1E). 
The mean IC50 values reported in Table 2, defined here as the concentration of drug required for 50% 
inhibition of viable cell number in vitro, obtained from each individual cytotoxicity curve, also reflect these 
differences where a wide variation in values was observed. In all cases, the TB exclusion assay showed the 
highest sensitivity for detecting cytotoxicity giving the lowest IC50 values for all the compounds compared 
to the other three enzyme-based methods and in both cell lines, indicating that this assay might over-
estimate the actual toxicity of the compounds. These differences were always statistically significant except 
in the case of U373MG cells in the presence of paraquat assessed with the Acid Phosphatase assay. Instead, 
the IC50 values obtained for all the compounds using the Alamar Blue assay were, in general, the highest in 
both cell lines compared to the other three test methods, indicating that it has the lowest sensitivity in terms 
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of viable cell number determination. For instance, the IC50 of etoposide in both cell lines was less than 60 
µM using the Trypan Blue exclusion assay, however, the Alamar Blue assay failed to produce an IC50 value 
in either cell line up to concentrations of 300 µM. Additionally the Acid Phosphatase assay also showed 
high IC50 values in both cell lines being ~240 µM – much higher than the values produced by the gold 
standard direct observation which returned IC50 values 4-fold less. Results such as these in a HTS setting 
for glioblastoma, may direct an automatic system to disregard a potentially beneficial compound as being 
without and hence to misjudge the full benefits of compounds that are being screened. 
Concerning with the sensitivity of the assays used here, the inhibitory concentrations values (IC50) were 
considered as the metric of interest for establishing the reliabilities among the different methodologies. In 
contrast to the enzyme-based assays performed in 96-well formats, in the present study Trypan Blue Assay 
was the in vitro assay with the highest sensitivity for detecting cytotoxicity in both cell lines after treatment 
with carboplatin, etoposide and paraquat. Since it was introduced in 1960, the use of Trypan Blue has been 
considered a direct in vitro assay for quantifying cell numbers, and additionally, due to the uptake of the 
blue dye by cells with compromised membranes, this method offers the advantage over others of 
distinguishing between dead/dying and live cells (Tran et al., 2011). At present, this assay is still considered 
as the least expensive requiring no specialized or expensive equipment and the easiest to perform, despite 
its low-precision when it is used for a large number of samples (Kim et al., 2011). Automatic cell counting 
techniques are highly attractive alternatives to the Trypan Blue exclusion method of determining cell 
number, however technical requirements and high financial barriers to entry means that this approach is 
often not available to research organisations with restricted budgets, such as Universities or small/start up 
biotechnology companies.  
The MTT assay is generally believed to be driven exclusively by the succinate dehydrogenase in the 
mitochondria of metabolically active cells which reduce it into its coloured formazan product. However, 
several studies have recently indicated that other intracellular enzymes such as NAD(P)H-dependent 
oxidoreductases can also be responsible for the tetrazolium salt reduction (van Meerloo et al., 2011) and 
that damaged mitochondria may still be able to reduce tetrazolium salts. Based on the premise that MTT 
reduction is proportional to the number of viable cells, evidence suggests that this non-specific dye 
reduction could lead to underestimate results of cytotoxicity (Hamid et al., 2004, Martin and Clynes, 1993). 
Indeed, Jo et al. recently reported that the MTT assay was unreliable for assessing cytotoxicity induced by 
different ethanol concentrations on primary glioma cells GBL-13 and GBL-15, stating that a better 
toxicological sensitivity was obtained when U87MG and U373MG were used (Jo et al., 2015). Rivera and 
Miller found that Neutral Red uptake which measures lysosomal integrity was more sensitive for measuring 
the changes in C6 glioma cells viability after 6 h of dinitrobenzene exposure in contrast with the MTT 
assay, which did not show any response within the range of concentrations used (Rivera and Miller, 2008). 
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The MTT assay also proved to be less sensitive than the Trypan Blue assay in human hepatoma cells 
(HepG2) for detecting radiation-induced cell viability (Chung et al., 2015). Interestingly, in our study the 
IC50 for carboplatin detected by the MTT assay in U87MG cells (223±23 µM) compares favourably with 
the toxicological data described by Pendylala and Creaven who reported a similar IC50 value after 48 h of 
carboplatin exposure on the same cell line (Pendyala and Creaven, 1993).  
Over the last 50 years, the use of the Alamar Blue assay has gained acceptance for measuring cell 
proliferation and cytotoxicity due to its versatility and simplicity, combined with the advantage of 
measuring viable cell number over time and allowing multiple analytic assays to be performed on the same 
samples, unlike the MTT assay (O'Brien et al., 2000). However, contrary to the evidence proposing the 
Alamar Blue assay as being one of the most sensitive in vitro cytotoxic assays, our results suggest that this 
is not always the case, since we observed the lowest sensitivity in both glioblastoma cell lines and for all 
three drug models. This finding could possibly be due to these particular cell lines and hence peculiar to 
this study. Although this method has been recognised for giving reproducible cytotoxicity profiles, some 
inherent limitations have recently been highlighted. Similar to the MTT reduction, resazurin reduction to 
resorufin may not be entirely restricted to changes in mitochondrial function suggesting that microsomal 
enzymes also play a role, leading to an underestimation of the potential cytotoxicity induced by chemicals 
(Gonzalez and Tarloff, 2001). An important consideration of these metabolic assays is that the reduction of 
the substrates which is affected by changes in intracellular metabolic activity may not have a direct effect 
on the overall number of viable cells since these assays cannot distinguish between quiescent and actively 
dividing cells (Quent et al., 2010).  
Contrary to the MTT and Alamar Blue assays, the Acid Phosphatase method estimates the number of 
viable cells by detecting alterations of the lysosomal membranes. Lysosomes are multifunctional organelles 
well known for containing a great quantity of  hydrolytic enzymes including Acid Phosphatase. An increase 
in the amount of this enzyme due to lysosomal labilisation induced by different chemical insults has been 
considered as a marker of cellular damage (Yang et al., 1996). However, some studies have postulated that 
variations in Acid Phosphatase activity can be affected by the cell density and cell cycle distribution which 
consequently lead to artefacts in the fluorescent signal generated (Martin and Clynes, 1993). This 
assumption was later confirmed by a study undertaken by Friedrich and colleagues who observed lower 
cellular signal intensities in confluent human colon carcinoma cell lines (Friedrich et al., 2007).  In our 
study, the Acid Phosphatase assay appears to be the most suitable assay for detecting differences among 
the two cell lines when a toxicant such as paraquat is used.  
3.2 Different cytotoxic responses detected between the two glioblastoma cell lines upon exposure to 
chemical compounds using different assays 
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The two glioblastoma cell lines, U373MG and U87MG differ in their cytotoxic responses according to 
the chemical compound used. The IC50 values reported in Table 2 indicate that U87MG cells are generally 
more sensitive to the two anti-cancer drugs, carboplatin and etoposide than U373MG cells since the IC50 
values are lower. Indeed, these two cell lines differ in their expression of the multi-drug resistance 
associated protein (MRP) where it is almost 4-fold more expressed in U373MG cells compared to U87MG 
cells which accounts for the increased resistance observed against etoposide and other drugs with respect 
to U87MG cells (Mohri et al., 2000). Furthermore, U373MG cells differ from U87MG cells in that they 
have mutant p53 and phosphatase and tensin homolog (PTEN), whereas U87MG, normally considered to 
be drug-sensitive, harbour a wild-type p53 gene but without expressing the functional protein to any 
measurable extent due to Mdm2 overexpression which destabilizes it (Weller et al., 1998).  Interestingly, 
the IC50 values for U87MG cells are not too dissimilar from each other when comparing the two drugs for 
each individual assay, except for the MTT assay where a higher IC50 value was obtained in the presence of 
carboplatin (248 M vs 141 M). This suggests that both drugs are just as effective at similar concentrations 
on U87MG cells. These considerations can also be deduced from the cytotoxicity profiles in Fig. 1A and 
1B. On comparing the IC50 values of U373MG cells obtained with the two anti-cancer drugs, the results 
show that these cells are more resistant to carboplatin than to etoposide regardless of the large variability 
in the IC50 values obtained with the different assays. In accordance with our results, variability between 
cytotoxicity assays using cell counting, Alamar Blue and Acid Phosphatase assays and volume 
determination has also been reported on three-dimensional stem cell neurospheres after etoposide treatment 
(Ivanov et al., 2014). Similarly, Gajski et al., (Gajski et al., 2016) observed inter-assay differences in human 
glioblastoma A1235 cells treated with the biotoxin, bee venom (BV). By using the MTT, Crystal violet and 
Trypan blue exclusion assays, they found that at higher concentrations of BV tested, the Crystal violet assay 
was very sensitive compared to the other two assays which were more comparable with each other.  
With regards to cytotoxicity induced by a non-anticancer agent, such as the toxin, paraquat, it is 
interesting to observe that U373MG cells, normally considered to be more drug-resistant than U87MG cells 
(Siegelin et al., 2009,Ravizza et al., 2004,Mohri et al., 2000) appear to be less resistant in the presence of a 
toxicant. This reduced sensitivity with respect to U87MG cells has also been observed by Datta et al. when 
testing the resistance of these two cell lines against cisplatin (Datta et al., 2004). This can be inferred by 
both the lower IC50 values and by the cytotoxicity profiles (Fig. 1C and 1F). The differences between the 
two cell lines can also be seen by the profiles reported in Fig. 2A-C, which compare the effect of each 
individual drug using the assay which resulted the most sensitive one for discerning the differences between 
them, excluding the TB assay. While paraquat indeed showed potent cytotoxic effects and lower IC50 values 
than the other compounds tested, especially in the more drug-resistant cells U373MG, it also showed the 
same discrepancies as the chemotherapeutic compounds when each method was tested against each other 
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as seen in Table 2. As mentioned above, the Acid Phosphatase assay (Fig. 2A) appears to be particulary 
sensitive for discriminating the differences in cytotoxicity to toxicants among the two cell lines since there 
is large gap in the IC50 values (Table 2). Instead, for the anti-cancer agents, the Acid Phosphatase assay is 
the least ideal one for determining their drug sensitivities, since it showed the smallest variability in IC50. 
In these cases, the MTT assay appears to be the most sensitive one for determining differences in drug-
resistance to anti-cancer agents. Although the Alamar Blue assay shows the greatest variability in IC50 
values in the case of carboplatin, as pointed above, it appears to over-estimate cytotoxicity.  
These outcomes are of particular concern in the context of drug discovery and development, especially 
given the trend towards large scale reliance upon HTS as a primary research tool. If, as suggested by these 
results there are large scale variations between cytotoxicity assays across a range of compounds with 
varying mechanisms of cytotoxicity, then it is possible that the true IC50 value of valuable and beneficial 
compounds for glioblastoma may have been missed through over/underestimation. This highlights the 
importance of reliability and accuracy in pre-animal models such as in vitro models of cytotoxicity.  
Variations between methods and utilised materials are to be expected in the course of scientific enquiry. 
However, improving the accuracy and reliability of the screening methods applied to broad screening of 
potential anti-cancer compounds, constitutes an imperative target for all major pharmaceutical companies, 
as well as the smaller players in the drug discovery and development industry. Hence research efforts should 
be directed to correct and optimize the assays and methods of investigation that are being used in order to 
maximise the benefits of research. Reduction in costs in terms of correct decision making early in the 
process, will hopefully lead to reductions in the failure rate of inappropriate compounds entering expensive 
and involved clinical trials. 
 
4. Conclusions  
 In conclusion, the comparison between the four different in vitro assays used for assessing the 
cytotoxicity on two different glioblastoma cell lines, suggests that even when combining several endpoints 
such as mitochondrial functions, lysosomal activity, and membrane integrity, a reliable and uniform toxicity 
profile was not achieved. Indeed, variations between IC50 values were seen in all experiments with 
differences observed between testing methods, cell lines and cytotoxic agents under investigation. A 
thorough knowledge of the advantages and limitations of each in vitro assay prior to use may help avoid 
underestimating or overestimating toxicological results and could lead to better predictive in vivo responses. 
Since many cytotoxic studies have been and are being conducted using patient-derived primary 
glioblastoma cells to perform patient-specific research, one needs to carefully interpret the cytotoxic results 
if obtained from the first generation MTT assays and to run other cytotoxic assays in parallel in order to 
produce more reliable and accurate cytotoxic results. 
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Legends to Figures 
Figure 1. Comparison of different assays on viable cell number of U373MG and U87MG glioblastoma 
cells. Cells were exposed to increasing concentrations of either Carboplatin, Etoposide or Paraquat for 48 
h and cell survival was assessed using different assays: Acid Phosphatase (▲), MTT (•), Alamar Blue (■), 
Trypan Blue (▼). The results are expressed as the percentage of viable cells compared to the control. Data 
are presented as mean ± SEM of at least 18 values from at least 3 independent experiments, except for (*) 
which represent the mean ± SEM of 12 values from two independent experiments.  
 
Figure 2. Comparison of different drugs on viable cell number of glioblastoma cells. U373MG (•) and 
U87MG (■) cells were exposed to increasing concentrations of Paraquat, Etoposide, Carboplatin for 48 h 
and cell survival was assessed using different assays: Acid Phosphatase (A), MTT (B), Alamar Blue (C). 
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The results are expressed as the percentage of viable cells compared to the control. Data are presented as 
mean ± SEM of at least 18 values from at least 3 independent experiments. 
  
